About this role:
Outcome Capital, a Boston-based life sciences dedicated investment banking and strategic advisory firm, is seeking an exceptional candidate to join the growing team as Analyst / Senior Analyst. The candidate will be a strategic thinker and collaborative team-oriented individual seeking to join a growing organization. Candidates will be intellectually curious, open-minded and passionate about driving scientific development through M&A, capital raise, partnership, and other corporate transactions.
Who you are:
Specific responsibilities include:
Skills and experience:
About Outcome Capital
Outcome Capital is a highly specialized life sciences investment banking and strategic advisory firm, providing a value-added, market-aligned approach to mergers & acquisitions, partnerships, private equity financings, and strategic advisory. The firm operates with a ‘strategy-led execution’ approach to value enhancement by assisting management teams and their boards navigate both financial and strategic markets. Outcome Capital’s strength stems from its multi-disciplinary, industry-dedicated experts who draw from their wide range of scientific, operational, strategic, and transactional expertise. Comprised of former CEOs, business development executives, venture capitalists, scientists and clinicians, and MBAs, our team is driven to assist life sciences companies.
Outcome is proud of its unique culture of intellectual agility and openness, data-driven perspectives, strategic thinking, and commitment to teamwork. We are devoted to providing unmatched transaction advisory to our clients and share an uncompromised dedication to the life sciences industry’s success.
Interested candidates should share a current resume, Statement of Interest, and transaction history, if applicable.
Candidates must be permitted to work in U.S. This position does not offer sponsorship.
Location: Boston, MA
Full-Time
Outcome Capital is an Equal Opportunity Employer committed to a diversified and inclusive workforce. To apply, please write to careers@outcomecapital.com
This article examines the quiet but profound reset underway in U.S. biotech, triggered by a rare combination of forces: delayed or reduced federal funding, large pharma cutting mid-stage partnerships, and venture capital pulling back as exits evaporate. Based on insights from Dr. Stanislav Glezer, it reveals a market splitting in two — with capital chasing late-stage and very early assets while Phase 1–2 companies are stranded in the middle. The piece also exposes how government uncertainty, shrinking NIH support, and overlooked patient-behavior realities are forcing founders to rethink their entire company lifecycle. In today’s environment, survival requires new strategies, new geographies, and a deeper understanding of human factors that no protocol can fix.
Read More
Outcome Capital Life Science Market Pulse October 2025 Click to view our LifeSciences Pulse Newsletter
DownloadWould you like to learn more about working with Outcome Capital or discuss your specific needs?